Multifocal prostate cancer: biologic, prognostic, and therapeutic implications

Human Pathology

Volumn 41, Issue 6, 2010, Pages 781-793

  Andreoiu, Matei ^a   Cheng, Liang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinogenesis; Field effect; Gleason grade; Molecular genetics; Multifocal; Precursor lesions; Prostate; Prostatectomy; Prostatic intraepithelial neoplasia (PIN); Staging; TMPRSS2 ERG gene fusion; Tumor heterogeneity; Tumor volume

Indexed keywords

BRCA1 PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS;

BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 8P; CHROMOSOME ABERRATION; CRYOSURGERY; EXTERNAL BEAM RADIOTHERAPY; GENE LOCUS; GENE REARRANGEMENT; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MULTIPLE CANCER; NONHUMAN; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; RADIOFREQUENCY ABLATION; REVIEW; TUMOR LOCALIZATION;

ADENOCARCINOMA; HUMANS; MALE; NEOPLASMS, MULTIPLE PRIMARY; PROSTATIC NEOPLASMS;

EID: 77951887410     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.02.011     Document Type: Review

References (125)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
2. Bastacky S.I., Wojno K.J., Walsh P.C., Carmichael M.J., and Epstein J.I. Pathological features of hereditary prostate cancer. J Urol 153 (1995) 987-992
3. Kastendieck H. Correlations between atypical primary hyperplasia and carcinoma of the prostate. A histological study of 180 total prostatectomies. Pathol Res Pract 169 (1980) 366-387
4. Cheng L., Poulos C.K., Pan C., et al. Preoperative prediction of small volume cancer (<0.5 ml) in radical prostatectomy specimens. J Urol 174 (2005) 898-902
5. Byar D.P., and Mostofi F.K. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Cancer 30 (1972) 5-13
6. Cheng L., Jones T.D., Pan C.X., Barbarin A., Eble J.N., and Koch M.O. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18 (2005) 1022-1026
7. Greene D.R., Wheeler T.M., Egawa S., Weaver R.P., and Scardino P.T. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol 68 (1991) 499-509
8. Qian J., and Bostwick D.G. The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Pathol Res Pract 191 (1995) 860-867
9. Eichelberger L.E., and Cheng L. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 100 (2004) 2573-2576
10. Arora R., Koch M.O., Eble J.N., Ulbright T.M., Li L., and Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100 (2004) 2362-2366
11. Cheng L., Song S., Pretlow T.G., et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Can Inst 90 (1998) 233-237
12. Villers A., McNeal J.E., Freiha F.S., and Stamey T.A. Multiple cancers in the prostate. Cancer 70 (1992) 2313-2318
13. Cheng L., Pisansky T.M., Ramnani D.M., et al. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol 13 (2000) 113-118
14. Miller G.J., and Cygan J.M. Morphology of prostate cancer: the effect of multifocality on histological grade, tumor volume, and capsule penetration. J Urol 152 (1994) 1709-1713
15. Aihara M., Wheeler T.M., Ohori M., and Scardino P.T. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43 (1994) 60-67
16. Bostwick DG, Shan A, Qian J, et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. 1998;83:1995-2002.
17. Ruijter E., Van de Kaa C.A., Schalken J.A., Debruyne F.R., and Ruiter D.J. Histological grade heterogeneity in multifocal prostate cancer: biological and clinical implications. J Pathol 180 (1996) 295-299
18. von Eschenbach A.C. The biologic dilemma of early carcinoma of the prostate. Cancer 78 (1996) 326-329
19. Liu W., Laitinen S., Khan S., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15 (2009) 559-565
20. Zaridze D.G., and Boyle P. Cancer of the prostate: epidemiology and aetiology. Br J Urol 59 (1987) 493-502
21. Cooney K.A., McCarthy J.D., Lange E., et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 89 (1997) 955-959
22. Monroe K.R., Yu M.C., Kolonel L.N., et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1 (1995) 827-829
23. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274 (1996) 1371-1374
24. Whittemore A.S., Wu A.H., Kolonel L.N., et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 141 (1995) 732-740
25. Isaacs S.D., Kiemeney L.A., Baffoe-Bonnie A., Beaty T.H., and Walsh P.C. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 87 (1995) 991-996
26. Stellman S.D., and Wang Q.S. Cancer mortality in Chinese immigrants to New York City. Comparison with Chinese in Tianjin and with United States-born whites. Cancer 73 (1994) 1270-1275
27. Fischer N., Hellwinkel O., Schulz C., et al. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 43 (2008) 277-283
28. Schlaberg R., Choe D.J., Brown K.R., Thaker H.M., and Singh I.R. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci USA 106 (2009) 16351-16356
29. De Marzo A.M., Platz E.A., Sutcliffe S., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 4 (2007) 256-269
30. Epstein J.I. Precursor lesions to prostatic adenocarcinoma. Virchows Arch 454 (2009) 1-16
31. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 23 (1992) 273-279
32. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother Rep 50 (1966) 125-128
33. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. Veterans administration cooperative urologic research group. J Urol 111 (1974) 58-64
34. McNeal J.E., Bostwick D.G., Kindrachuk R.A., Redwine E.A., Freiha F.S., and Stamey T.A. Patterns of progression in prostate cancer. Lancet 1 (1986) 60-63
35. Stamey T.A. Clinical and morphometric observations on prostate cancer. Med Sect Proc (1988) 29-42
36. Brawn P.N. The dedifferentiation of prostate carcinoma. Cancer 52 (1983) 246-251
37. Cheng L., Bergstralh E.J., Slezak J., Cheville J.C., Zincke H., and Bostwick D.G. Dedifferentiation in metastatic progression of prostate cancer. Cancer 86 (1999) 657-663
38. McNeal J.E. Regional morphology and pathology of the prostate. Am J Clin Pathol 49 (1968) 347-357
39. McNeal J.E. The zonal anatomy of the prostate. Prostate 2 (1981) 35-49
40. McNeal J.E. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 23 (1992) 258-266
41. McNeal J.E., Redwine E.A., Freiha F.S., and Stamey T.A. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 (1988) 897-906
42. Garcia J.J., Al-Ahmadie H.A., Gopalan A., et al. Do prostatic transition zone tumors have a distinct morphology?. Am J Surg Pathol 32 (2008) 1709-1714
43. Greene D.R., Wheeler T.M., Egawa S., Dunn J.K., and Scardino P.T. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 146 (1991) 1069-1076
44. Augustin H., Erbersdobler A., Graefen M., et al. Differences in biopsy features between prostate cancers located in the transition and peripheral zone. BJU Int 91 (2003) 477-481
45. Stamey T.A., Sozen T.S., Yemoto C.M., and McNeal J.E. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol 159 (1998) 2009-2012
46. Noguchi M., Stamey T.A., McNeal J.E., and Yemoto C.E. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 163 (2000) 1751-1755
47. Augustin H., Erbersdobler A., Graefen M., et al. Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones. Prostate 55 (2003) 48-54
48. Noguchi M., Stamey T.A., McNeal J.E., and Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170 (2003) 459-463
49. Steuber T., Karakiewicz P.I., Augustin H., et al. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions. J Urol 173 (2005) 737-741
50. Shannon B.A., McNeal J.E., and Cohen R.J. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour. Pathology 35 (2003) 467-471
51. Al-Ahmadie H.A., Tickoo S.K., Olgac S., et al. Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy. Am J Surg Pathol 32 (2008) 229-235
52. Chun F.K., Briganti A., Jeldres C., et al. Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy. Eur Urol 51 (2007) 949-955 [discussion 955]
53. Sakai I., Harada K., Kurahashi T., Yamanaka K., Hara I., and Miyake H. Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones. Int J Urol 13 (2006) 368-372
54. Sakai I., Harada K., Hara I., Eto H., and Miyake H. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones. BJU Int 96 (2005) 528-532
55. Guo C.C., Zuo G., Cao D., Troncoso P., and Czemiak B.A. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 22 (2009) 866-871
56. Bostwick D.G., and Meiers I. Neoplasms of the prostate. In: Bostwick D.G., and Cheng L. (Eds). Urologic Surgical Pathology. 2nd ed. (2008), Elsevier/Mosby, Philadelphia 443-580
57. Bostwick D.G., and Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 17 (2004) 360-379
58. Cheng L., Paterson R.F., Beck S.D., and Parks J. Prostatic intraepithelial neoplasia: an update. Clin Prostate Cancer 3 (2004) 26-30
59. Montironi R., Mazzucchelli R., Lopez-Beltran A., Cheng L., and Scarpelli M. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol 4 (2007) 321-332
60. Qian J., Jenkins R.B., and Bostwick D.G. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 10 (1997) 1113-1119
61. Greene D.R., Taylor S.R., Wheeler T.M., and Scardino P.T. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res 51 (1991) 4084-4089
62. Emmert-Buck M.R., Vocke C.D., Pozzatti R.O., et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55 (1995) 2959-2962
63. Sakr W.A., Macoska J.A., Benson P., et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 54 (1994) 3273-3277
64. Qian J., Bostwick D.G., Takahashi S., et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55 (1995) 5408-5414
65. Emi M., Fujiwara Y., Nakajima T., et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 52 (1992) 5368-5372
66. Cunningham J., Lust J.A., Schaid D.J., et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 52 (1992) 1974-1980
67. Yaremko M.L., Wasylyshyn M.L., Paulus K.L., Michelassi F., and Westbrook C.A. Deletion mapping reveals two regions of chromosome 8 allele loss in colorectal carcinomas. Genes Chromosomes Cancer 10 (1994) 1-6
68. Fujiwara Y., Monden M., Mori T., Nakamura Y., and Emi M. Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma. Cancer Res 53 (1993) 857-860
69. Knowles M.A., Shaw M.E., and Proctor A.J. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 8 (1993) 1357-1364
70. Kobayashi M., Ishida H., Shindo T., et al. Molecular analysis of multifocal prostate cancer by comparative genomic hybridization. Prostate 68 (2008) 1715-1724
71. Tomlins S.A., Mehra R., Rhodes D.R., et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39 (2007) 41-51
72. Ahmed H.U. The index lesion and the origin of prostate cancer. N EnglJ Med 361 (2009) 1704-1706
73. Gurel B., Iwata T., Koh C.M., et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21 (2008) 1156-1167
74. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8 (2008) 497-511
75. True L., Coleman I., Hawley S., et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 103 (2006) 10991-10996
76. Jenkins R.B., Qian J., Lieber M.M., and Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57 (1997) 524-531
77. Schmidt H., DeAngelis G., Eltze E., Gockel I., Semjonow A., and Brandt B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 66 (2006) 8959-8965
78. Tomlins S.A., Mehra R., Rhodes D.R., et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66 (2006) 3396-3400
79. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
80. Mehra R., Han B., Tomlins S.A., et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 67 (2007) 7991-7995
81. Soller M.J., Isaksson M., Elfving P., Soller W., Lundgren R., and Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45 (2006) 717-719
82. Perner S., Demichelis F., Beroukhim R., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66 (2006) 8337-8341
83. Perner S., Mosquera J.M., Demichelis F., et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31 (2007) 882-888
84. Demichelis F., Fall K., Perner S., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007) 4596-4599
85. Barry M., Perner S., Demichelis F., and Rubin M.A. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70 (2007) 630-633
86. Wang J., Cai Y., Ren C., and Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66 (2006) 8347-8351
87. Gopalan A., Leversha M.A., Satagopan J.M., et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69 (2009) 1400-1406
88. Saramaki O.R., Harjula A.E., Martikainen P.M., Vessella R.L., Tammela T.L., and Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14 (2008) 3395-3400
89. Henrique R., Jeronimo C., Teixeira M.R., et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4 (2006) 1-8
90. Henrique R., Jeronimo C., Hoque M.O., et al. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1274-1278
91. Jeronimo C., Henrique R., Hoque M.O., et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10 (2004) 8472-8478
92. Cheville J.C., Karnes R.J., Therneau T.M., et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 26 (2008) 3930-3936
93. Beahrs O.H., Henson D.E., Hutter R.V.P., and Kennedy B.J. AJCC Manual for staging of cancer. 4th ed. (1992), Lippincott, Philadelphia
94. Catalona W.J. Management of cancer of the prostate. N Engl J Med 331 (1994) 996-1004
95. Catalona W.J., and Smith D.S. Detection of early prostate cancer: serendipitous or systematic?. JAMA 279 (1998) 1439-1441
96. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
97. Zincke H., Oesterling J.E., Blute M.L., Bergstralh E.J., Myers R.P., and Barrett D.M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850-1857
98. Fleming I.D., Phillips J.L., Menck H.R., Murphy G.P., and Winchester D.P. The National Cancer Data Base report on recent hospital cancer program progress toward complete American Joint Committee on Cancer/TNM staging. Cancer 80 (1997) 2305-2310
99. Cagiannos I., Graefen M., Karakiewicz P.I., et al. Analysis of clinical stage T2 prostate cancer: Do current subclassifications represent an improvement?. J Clin Oncol 20 (2002) 2025-2030
100. Edge S., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., and Trotti A. American Joint Committee on Cancer Staging Manual. 7th ed. (2010), Springer, New York
101. Greene F.L., Page D.L., Flemming I.D., et al. American Joint Committee on Cancer Staging Manual. 6th ed. (2002), Springer-Verlag, New York
102. Han M., Walsh P.C., Partin A.W., and Rodriguez R. Ability of the 1992 and 1997 American Joint Committee on Cancer Staging Systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. J Urol 164 (2000) 89-92
103. Iyer R.V., Hanlon A.L., Pinover W.H., and Hanks G.E. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy. Cancer 85 (1999) 1816-1821
104. Bostwick D.G., Myers R.P., and Oesterling J.E. Staging of prostate cancer. Semin Surg Oncol 10 (1994) 60-72
105. Hoedemaeker R.F., Vis A.N., and Van der Kwast T.H. Staging prostate cancer. Microsc Res Tech 51 (2000) 423-429
106. Pan C., Potter S.R., Partin A.W., and Epstein J.I. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 24 (2000) 563-569
107. Chan T.Y., Partin A.W., Walsh P.C., and Epstein J.I. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 56 (2000) 823-827
108. Hattab E.M., Koch M.O., Eble J.N., Lin H., and Cheng L. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. J Urol 175 (2006) 1695-1699
109. Sim H.G., Telesca D., Culp S.H., et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 179 (2008) 1775-1779
110. Patel A.A., Chen M.H., Renshaw A.A., and D'Amico A.V. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 298 (2007) 1533-1538
111. Harnden P., Shelley M.D., Coles B., Staffurth J., and Mason M.D. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 8 (2007) 411-419
112. Trock B.J., Guo C.C., Gonzalgo M.L., Magheli A., Loeb S., and Epstein J.I. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol 182 (2009) 1364-1370
113. Stamey T.A., McNeal J.E., Yemoto C.M., Sigal B.M., and Johnstone I.M. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395-1400
114. Cheng L., Koch M.O., Juliar B.E., et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol 23 (2005) 2911-2917
115. Cheng L., Davidson D.D., Lin H., and Koch M.O. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 110 (2007) 1967-1972
116. Gburek B.M., Kollmorgen T.A., Qian J., D'Souza-Gburek S.M., Lieber M.M., and Jenkins R.B. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. J Urol 157 (1997) 223-227
117. Djavan B., Susani M., Bursa B., Basharkhah A., Simak R., and Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 5 (1999) 139-142
118. Polascik T.J., and Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology 74 (2009) 726-730
119. Koch M.O., Gardner T., Cheng L., Fedewa R.J., Seip R., and Sanghvi N.T. Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J Urol 178 (2007) 2366-2371
120. Barqawi A., and Crawford E.D. Focal therapy in prostate cancer: future trends. BJU Int 95 (2005) 273-274
121. Hövels A.M., Heesakkers R.A., Adang E.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63 (2008) 387-395
122. Cupp M.R., Bostwick D.G., Myers R.P., and Oesterling J.E. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 153 (1995) 1543-1548
123. Leibovich B.C., Blute M.L., Bostwick D.G., et al. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology 56 (2000) 726-729
124. Chen M.E., Johnston D.A., Tang K., Babaian R.J., and Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 89 (2000) 1800-1809
125. Erbersdobler A., Huhle S., Palisaar J., et al. Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone. Prostate Cancer Prostatic Dis 5 (2002) 279-284